How Celgene Won With This Earnings Report
Overall, investors were content after Celgene reported its second-quarter financial results, with wins on both the top and bottom lines.
Overall, investors were content after Celgene reported its second-quarter financial results, with wins on both the top and bottom lines.
Amgen is expected to report its second-quarter financial results after the markets close on Wednesday. Will it go the same way as Gilead Sciences did earlier this week?
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
A new JPMorgan research report says it time to buy the health care sector and sell consumer staples, which have run hard this year.
The short interest data are out for the July 15 settlement date. Short interest increased across many of these selected biotech stocks.
Overall, the Gilead Sciences report was not good and investors took to dumping the stock. On the other hand, this could provide a buying opportunity since shares are just off of their 52-week lows.
As one of the largest pharmaceutical companies on the street, Eli Lilly helps to set the tempo for the industry. Currently the company is in the middle of a very dynamic product launch.
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
Although Gilead Sciences is one of the world’s leading biotech companies, an earnings beat in its latest report was not enough to satisfy investors.
Gilead Sciences is scheduled to release its second-quarter financial results after the markets close on Monday.
One key reason UnitedHealth has done well is that it has managed the downward pressure Obamacare has put on may insurance firms.
Puma Biotechnology watched its shares make a handy gain on Friday morning after the firm released updated results from its late-stage breast cancer trial.
Relypsa made a splash in the markets on Thursday morning after the company announced an acquisition agreement.
Shares of Progenics Pharmaceuticals and Valeant Pharmaceuticals made handy gains in the market on Wednesday following a key FDA approval that could be a real turning point for the companies.
As one of the largest health care companies on the market, Johnson & Johnson helps set a direction for the industry. Strength within its pharmaceutical segment helped push this company to new highs with…